RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing RulesGlobeNewsWire · 2 days ago
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3GlobeNewsWire · 5 days ago
RxSight Appoints Eye Care Industry Leaders to Drive Commercial TransformationGlobeNewsWire · 6 days ago
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the worldGlobeNewsWire · Oct 16, 2026
Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)Defense World · Oct 6, 2026
RxSight (NASDAQ:RXST) and Organigram Global (NASDAQ:OGI) Financial SurveyDefense World · Oct 6, 2026As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.33 | -$0.29 | Beat |
| May 6, 2026 | -$0.30 | -$0.38 | Miss |
| Feb 25, 2026 | -$0.33 | -$0.22 | Beat |
| Nov 5, 2025 | -$0.34 | -$0.24 | Beat |
| Aug 7, 2025 | -$0.25 | -$0.29 | Miss |
| May 7, 2025 | -$0.22 | -$0.20 | Beat |